Treats Parkinson’s disease. ANDA 212797, held by Xiamen LP Pharm. Pramipexole Dihydrochloride.
As of Nov 21, 2026, ANDA 212797 (Pramipexole Dihydrochloride), held by Xiamen LP Pharm, was first approved by FDA on Jun 11, 2021, with 2 approved supplements and 0 published complete response letters.
Pramipexole dihydrochloride extended-release tablets are indicated for the treatment of Parkinson’s disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 11, 2021 | Original application | Approved | None posted |
| Pramipexole Dihydrochloride0.375MG · tablet, extended release;oral | Pramipexole Dihydrochloride | Rx |
| Pramipexole Dihydrochloride0.75MG · tablet, extended release;oral | Pramipexole Dihydrochloride | Rx |
| Feb 19, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| May 26, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 11, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters